OBJECTIVE: To investigate the interrelationship between cardiac surgery, age, circulating concentrations of the vitamin D hormone 1,25-dihydroxyvitamin D, and clinical outcome. DESIGN: Prospective, monocentric, two-arm parallel study. SETTING: Tertiary Heart and Diabetes Center in the Federal State of North Rhine-Westphalia, Germany. PATIENTS: Twenty-nine cardiac surgical patients aged ≤ 65 yrs and 30 patients ≥ 75 yrs. MEASUREMENTS: We assessed 1,25-dihydroxyvitamin D and other biochemical parameters of mineral metabolism (calcium, phosphate, 25-hydroxyvitamin D, and parathyroid hormone), various inflammatory markers (C-reactive protein, interleukin-6 and 8), and different immunological parameters (CD4 and CD8 cells, monocyte HLA-DR expression). We collected blood samples preoperatively, immediately after surgery, and on postoperative days 1, 5, and 30. In addition, we assessed adverse outcome until discharge as a composite of myocardial infarction, low cardiac output syndrome, infection, stroke, or in-hospital death. RESULTS: There were significant transient cardiac surgery-related fluctuations in 1,25-dihydroxyvitamin D and the aforementioned parameters of mineral metabolism, inflammation, and immune status. Compared to younger patients, older patients had consistently lower 1,25-dihydroxyvitamin D and phosphate levels (p = .013 and p = .036, respectively) and significantly higher interleukin 6 and 8 levels (p = .008 and p < .001, respectively). Circulating 1,25-dihydroxyvitamin D was directly related to glomerular filtration rate (R(2) = .227; p < .001) and inversely related to interleukin 6 (R(2) = .105; p = .012). The rate of adverse outcome tended to be higher in older than in younger patients (20.0% vs. 3.5%; p = .081). In risk score-adjusted logistic regression analysis, adverse outcome risk decreased by 7.7% (SE: 3.7%) for each pmol/L increment in 1,25-dihydroxyvitamin D (p = .037). CONCLUSIONS: Circulating 1,25-dihydroxyvitamin D levels fluctuate in relation to cardiac surgery. Low 1,25-dihydroxyvitamin D levels are associated with inflammatory processes and age-related differences in clinical outcome. Future studies should determine whether therapies aimed at treating low 1,25-dihydroxyvitamin D levels can improve the outcome in older cardiac surgery patients.
OBJECTIVE: To investigate the interrelationship between cardiac surgery, age, circulating concentrations of the vitamin D hormone 1,25-dihydroxyvitamin D, and clinical outcome. DESIGN: Prospective, monocentric, two-arm parallel study. SETTING: Tertiary Heart and Diabetes Center in the Federal State of North Rhine-Westphalia, Germany. PATIENTS: Twenty-nine cardiac surgical patients aged ≤ 65 yrs and 30 patients ≥ 75 yrs. MEASUREMENTS: We assessed 1,25-dihydroxyvitamin D and other biochemical parameters of mineral metabolism (calcium, phosphate, 25-hydroxyvitamin D, and parathyroid hormone), various inflammatory markers (C-reactive protein, interleukin-6 and 8), and different immunological parameters (CD4 and CD8 cells, monocyte HLA-DR expression). We collected blood samples preoperatively, immediately after surgery, and on postoperative days 1, 5, and 30. In addition, we assessed adverse outcome until discharge as a composite of myocardial infarction, low cardiac output syndrome, infection, stroke, or in-hospital death. RESULTS: There were significant transient cardiac surgery-related fluctuations in 1,25-dihydroxyvitamin D and the aforementioned parameters of mineral metabolism, inflammation, and immune status. Compared to younger patients, older patients had consistently lower 1,25-dihydroxyvitamin D and phosphate levels (p = .013 and p = .036, respectively) and significantly higher interleukin 6 and 8 levels (p = .008 and p < .001, respectively). Circulating 1,25-dihydroxyvitamin D was directly related to glomerular filtration rate (R(2) = .227; p < .001) and inversely related to interleukin 6 (R(2) = .105; p = .012). The rate of adverse outcome tended to be higher in older than in younger patients (20.0% vs. 3.5%; p = .081). In risk score-adjusted logistic regression analysis, adverse outcome risk decreased by 7.7% (SE: 3.7%) for each pmol/L increment in 1,25-dihydroxyvitamin D (p = .037). CONCLUSIONS: Circulating 1,25-dihydroxyvitamin D levels fluctuate in relation to cardiac surgery. Low 1,25-dihydroxyvitamin D levels are associated with inflammatory processes and age-related differences in clinical outcome. Future studies should determine whether therapies aimed at treating low 1,25-dihydroxyvitamin D levels can improve the outcome in older cardiac surgery patients.
Authors: Francesca De Vita; Fulvio Lauretani; Juergen Bauer; Ivan Bautmans; Michelle Shardell; Antonio Cherubini; Giuliana Bondi; Giovanni Zuliani; Stefania Bandinelli; Mario Pedrazzoni; Elisabetta Dall'Aglio; Gian Paolo Ceda; Marcello Maggio Journal: Age (Dordr) Date: 2014-08-03
Authors: H Bryant Nguyen; Blen Eshete; K H William Lau; Adarsh Sai; Mark Villarin; David Baylink Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240
Authors: Armin Zittermann; Joachim Kuhn; Jana B Ernst; Tobias Becker; Julia Larisch; Jens Dreier; Cornelius Knabbe; Jochen Börgermann; Jan F Gummert Journal: PLoS One Date: 2016-06-29 Impact factor: 3.240
Authors: Armin Zittermann; Jana B Ernst; Stefan Pilz; Jens Dreier; Joachim Kuhn; Cornelius Knabbe; Jan F Gummert; Michiel Morshuis; Hendrik Milting Journal: PLoS One Date: 2016-10-27 Impact factor: 3.240
Authors: Michael E Gerling; Matthew T James; Stephen B Wilton; Christopher Naugler; Danielle A Southern; P Diane Galbraith; Merril Knudtson; Lawrence de Koning Journal: J Am Heart Assoc Date: 2016-10-21 Impact factor: 5.501
Authors: Tyler Barker; Heidi T May; John R Doty; Donald L Lappe; Kirk U Knowlton; John Carlquist; Kristin Konery; Shannon Inglet; Ben Chisum; Oxana Galenko; Jeffrey L Anderson; Joseph B Muhlestein Journal: Physiol Rep Date: 2021-02
Authors: Ibrahim A Albahlol; Abdulrahman H Almaeen; Abdulrahman A Alduraywish; Umar F Dar; Tarek H El-Metwally Journal: Int J Med Sci Date: 2020-10-18 Impact factor: 3.738